Can a new drug combination help people with multiple myeloma that has returned after treatment?

For people living with multiple myeloma—a blood cancer—one of the hardest moments is when the disease returns after treatment. This is called relapsed or relapsed-refractory myeloma. This study asked a direct question: is a new three-drug combination safe and does it work for these patients? The treatment combined daratumumab (a targeted antibody drug) with two existing drugs, lenalidomide and dexamethasone. The study was done in two parts. First, researchers carefully tested increasing doses of daratumumab to find the safest, highest dose to use. Then, they expanded the trial to further explore that dose. The main goal was to see how many patients responded to the treatment, which is measured by the Overall Response Rate. The study enrolled 45 patients to answer these questions. The findings from this trial help doctors understand if this specific combination is a viable option for people who have run out of other treatments, offering a potential new direction when the cancer comes back.